- Home
- NTRB vs TLSA Comparison
NTRB vs TLSA Comparison
Compare NTRB & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- TLSA
- Stock Information
- Founded
- NTRB 2016
- TLSA 2013
- Country
- NTRB United States
- TLSA United Kingdom
- Employees
- NTRB N/A
- TLSA N/A
- Industry
- NTRB Industrial Specialties
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- TLSA Health Care
- Exchange
- NTRB Nasdaq
- TLSA Nasdaq
- Market Cap
- NTRB 77.9M
- TLSA 87.8M
- IPO Year
- NTRB N/A
- TLSA 2000
- Fundamental
- Price
- NTRB $6.17
- TLSA $1.20
- Analyst Decision
- NTRB
- TLSA
- Analyst Count
- NTRB 0
- TLSA 0
- Target Price
- NTRB N/A
- TLSA N/A
- AVG Volume (30 Days)
- NTRB 28.2K
- TLSA 145.8K
- Earning Date
- NTRB 12-11-2024
- TLSA 05-10-2024
- Dividend Yield
- NTRB N/A
- TLSA N/A
- EPS Growth
- NTRB N/A
- TLSA N/A
- EPS
- NTRB N/A
- TLSA N/A
- Revenue
- NTRB $1,803,816.00
- TLSA N/A
- Revenue This Year
- NTRB N/A
- TLSA N/A
- Revenue Next Year
- NTRB N/A
- TLSA N/A
- P/E Ratio
- NTRB N/A
- TLSA N/A
- Revenue Growth
- NTRB N/A
- TLSA N/A
- 52 Week Low
- NTRB $1.93
- TLSA $0.41
- 52 Week High
- NTRB $9.60
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- NTRB 50.57
- TLSA 65.44
- Support Level
- NTRB $5.24
- TLSA $0.83
- Resistance Level
- NTRB $6.40
- TLSA $0.92
- Average True Range (ATR)
- NTRB 0.71
- TLSA 0.09
- MACD
- NTRB -0.12
- TLSA 0.03
- Stochastic Oscillator
- NTRB 33.23
- TLSA 84.52
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.